Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 1, 2012. The report details a corporate action regarding the 3.00% Convertible Senior Notes due 2018 issued by GSK's wholly owned subsidiary, Human Genome Sciences (HGS).
Key Financial Metrics
The filing does not provide standard operating financial metrics such as revenue, profit, cash flow, margins, or overall debt levels. The only specific financial data disclosed relates to the HGS convertible notes:
- Notes Outstanding: $129,000 principal amount remains outstanding.
- Previously Converted: $494,371,000 principal amount has already been converted.
- Conversion Consideration: During the temporary increase period, holders receive $1,241.48 in cash per $1,000 principal amount converted.
- Conversion Rate: Temporarily increased to 87.1211 (from the standard 75.0469).
Material Changes
The primary material change is the temporary increase in the conversion rate for the HGS 3.00% Convertible Senior Notes. This change applies to conversions occurring between November 16, 2012, and December 18, 2012. Following GSK's acquisition of HGS, these notes are convertible solely into cash rather than equity.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance or operational outlook. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks and uncertainties. Specific risk factors are referenced in GSK's Annual Report 2011 (Exhibit 15.2 to Form 20-F). The filing notes that outside the temporary increase period, the notes will not be convertible until conditions in the indenture are met, which may not occur before August 15, 2018.
Investor Verification Checklist
- Verify the exact timing of the "Increase Period" (November 16 to December 18, 2012) for potential conversion.
- Confirm the remaining principal amount of $129,000 and the cash payout rate of $1,241.48 per $1,000 note.
- Review the indenture conditions for future convertibility after the Increase Period expires.
- Consult GSK's Annual Report 2011 for detailed risk factors associated with the HGS acquisition.